Backed by the Development Bank of Wales and Longbow Capital LLP, Calon has attracted over £8 million in equity investment. 

Other investors include high net worth individuals in the UK and Germany as well as corporate and employee investors.


Between 2020 and 2023, Calon is seeking to raise new investment of between £34 million to £43 million to fund clinical studies of the MiniVAD™ in the USA and Europe.  Calon is targeting CE mark for the MiniVAD™ around early 2024 by which time a US FDA Early Feasibility Study is due to have been completed.


Many UK individual investors into Calon up to this point have invested under the Enterprise Investment Scheme and it is expected that the investment rounds in 2020/21 will be EIS approved.


For further information on Calon and how to invest, please click here.

Calon Cardio-Technology Ltd
Institute of Life Science
Swansea University, Singleton Park
Swansea SA2 8PP

Wales, United Kingdom.

Telephone Number: +44 (0)1792 606356

General Information:

Investor Information: